The US Food and Drug Administration has approved Herceptin (trastuzumab) in combination with chemotherapy for HER2-positive metastatic stomach and gastroesophageal junction cancers, the drug’s manufacturer, Roche, announced. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
